IP Library › Patent Application 11109115
Patent Application
App. No. 11/109,115

Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/109,115
Abstract

Compositions and methods for the treatment of retina and optic nerve head neuropathy are disclosed. The compositions and methods are particularly directed to the use of neurotrophic factor stimulators, such as AIT-082 (neotrofin), in the treatment of glaucomatous neuropathy.

Claims (14)

1 . A composition for the treatment of retina or optic nerve head neuropathy comprising an effective amount of one or more neurotrophic factor stimulator(s) and a pharmaceutically acceptable vehicle.

2 . A composition according to claim 1 , wherein the neurotrophic factor stimulator is selected from the group consisting of AIT-082 (neotrofin), idebenone, ONO-2506, CB-1093, NS521 ((1-(1-butyl)-4-(2-oxo-1-benzimidazolone) piperidine, SS-701, KT-711 and clenbuterol.

3 . A composition according to claim 2 , wherein the neurotrophic factor stimulator is AIT-082 (neotrofin).

4 . A composition according to claim 1 , wherein the composition is an oral formulation.

5 . A composition according to claim 1 , wherein the composition is a topical ophthalmic, or intraocular formulation.

6 . A composition according to claim 3 , wherein the composition is an oral formulation.

7 . A composition according to claim 3 , wherein the composition is a topical ophthalmic, or intraocular formulation.

8 . A method for the treatment of retina or optic nerve head neuropathy which comprises administering to a mammal a composition comprising an effective amount of one or more neurotrophic factor stimulator(s) and a pharmaceutically acceptable vehicle.

9 . A method according to claim 8 , wherein the neurotrophic factor stimulator is selected from the group consisting of: AIT-082 (neotrofin), idebenone, ONO-2506, CB-1093, NS521 ((1-(1-butyl)-4-(2-oxo-1-benzimidazolone) piperidine, SS-701, KT-711 and clenbuterol.

10 . A method according to claim 9 , wherein the neurotrophic factor stimulator is AIT-082 (neotrofin).

11 . A method according to claim 8 , wherein the composition is an oral formulation.

12 . A method according to claim 8 , wherein the composition is a topical ophthalmic, or intraocular formulation.

13 . A method according to claim 10 , wherein the composition is an oral formulation.

14 . A method according to claim 10 , wherein the composition is a topical ophthalmic, or intraocular formulation.

Assignments (1)
MERGER Recorded Jul 21, 2008
From: ALCON MANUFACTURING, LTD.
To: ALCON RESEARCH, LTD.
Reel/Frame 021266/0729 →